Is Definium Therapeutics, Inc. (DFTX) a Buy, Sell, or Hold?
Definium Therapeutics, Inc.
NASDAQ:DFTX
$45.98 USD
$2.33 (5.34%)
- Volume
- 1.42M
- Average Volume
- 4.53M
- Market Capitalization
- $5.01B
- P/E Ratio
- -18.39
- Dividend Yield
- 0.00%
- Price Target
- $49.00
- Year High
- $49.20
- Year Low
- $12.88
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.69
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert Barrow |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DFTX |
| CUSIP | 24477V105 |
| CIK | 0001813814 |
| Web | https://definiumtx.com |
| Phone | 212 220 6633 |
| Currency | USD |
| Employees | 105 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.69 |
| Quick Ratio | 4.69 |
| Cash Ratio | 3.24 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.32 |
| Price / Cash Flow | -34.90 |
| Price / Book | 17.94 |
Price Target and Rating
| Average Stock Price Forecast | $49.00 |
| High Stock Price Forecast | $60.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -6.16% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.06 |
| Trailing P/E Ratio | -18.39 |
| PEG Ratio | 0.24 |
| P/E Growth | 0.24 |
| Net Income | $-183.79M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -102.48% |
| Return on Assets | -59.19% |
Financials Score
| AltmanZ Score | 20.09 |
| Piotroski Score | 2.00 |
| Working Capital | 299.45M |
| Total Assets | 401.29M |
| Ebit | -222.99M |
| Market Cap | 4.76B |
| Total Liabilities | 122.44M |
Poll Results
About Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York. ...
2026-07-14 10:56:15
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2026-07-14 07:00:00
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced results from a new healthcare claims study of treatment patterns of newly diagnosed and established GAD patients, including pharmacotherapy use, discontinuation, switching and treatment progression. The fi.
Definium Therapeutics Announces New Employee Inducement Grants
2026-07-06 16:01:00
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026.
2026-06-26 09:30:00
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026. NEW YORK and TORONTO, June 26, 2026 /PRNewswire/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule.
2026-06-25 16:15:00
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the closing of its previously announced underwritten public offering of 23,676,471 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase 3,088,23.
Biotech ETF Index Surges 10% After Rebalance
2026-06-25 11:31:47
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
2026-06-23 22:00:00
Definium Therapeutics, Inc. (Nasdaq: DFTX) (the âCompanyâ or âDefiniumâ), a late-stage clinical biopharmaceutical company developing a new generation o
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
2026-06-23 21:57:00
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de.
Frequently Asked Questions
-
What is the current Definium Therapeutics, Inc. (DFTX) stock price?
-
Definium Therapeutics, Inc.(NASDAQ:DFTX) stock price is $45.98 in the last trading session. During the trading session, DFTX stock reached the peak price of $49.2 while $12.882 was the lowest point it dropped to. The percentage change in DFTX stock occurred in the recent session was 5.34% while the dollar amount for the price change in DFTX stock was $2.33.
-
DFTX's industry and sector of operation?
-
The NASDAQ listed DFTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DFTX?
-
Peter Mack | Senior Vice President of Pharmaceutical Development & Operations
Beth Calitri | Vice President of Corporate Communications
Gitanjali Jain | VP & Head of Investor Relations
Stephanie Fagan | Chief Corporate Affairs Officer
Scott Freeman | Co-Founder & Clinical Advisor -
How many employees does DFTX have?
-
Number of DFTX employees currently stands at 105. DFTX operates from One World Trade Center, New York, NY 10007, US.
-
Link for DFTX official website?
-
Official Website of DFTX is: https://definiumtx.com
-
How do I contact DFTX?
-
DFTX could be contacted at phone #212 220 6633 and can also be accessed through its website. DFTX operates from One World Trade Center, New York, NY 10007, US.
-
How many shares of DFTX are traded daily?
-
The average number of DFTX shares traded daily for last 3 months was 4.53M.
-
What is the market cap of DFTX currently?
-
The market value of DFTX currently stands at $5.01B with its latest stock price at $45.98